

Supplementary file 1

Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer

Laura Cabeza^{1,2,3}, Mazen M. El-Hammadi⁴, Raul Ortiz^{1,2,3}, Maria D. Cayero-Otero⁴, Julia Jiménez-López^{1,3}, Gloria Perazzoli^{1,3}, Lucia Martin-Banderas⁴, Jose M. Baeyens⁵, Consolación Melguizo^{1,2,3*}, Jose Prados^{1,2,3}

¹Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain

²Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18071 Granada, Spain

³Biosanitary Institute of Granada (ibs.GRANADA), SAS-University of Granada, 18014 Granada, Spain

⁴Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Seville, 41012 Sevilla, Spain

⁵Department of Pharmacology, Institute of Neuroscience, Biomedical Research Center (CIBM), University of Granada, 18100, Granada, Spain




Fig. S1. Toxicity assay of the blank PLGA NPs. PLGA NPs without drug were tested in all breast cell lines (MCF-7, MDA-MB-231, T47D, SK-BR-3, MCF-10A, E0771) at different concentrations (0.1-100 nM) to determine modulation of the cell proliferation. Cells were exposed for 4 days to NPs with a renewal of medium and treatment every 48 hours. Data were represented as the mean value \pm SD of triplicate cultures.